Document is current

Article History

Received: 13 March 2023

Accepted: 7 August 2023

First Online: 12 September 2023

Declarations

:

: All participants provided written informed consent to take part in the study, which was conducted according to the Declaration of Helsinki and subsequent revisions. Ethical approval was obtained from the regional Human Ethics Committee of Stockholm and the Faculty of Medicine and Radiation Hazard Ethics Committee of Uppsala University Hospital, Sweden.

: Not applicable.

: KC, CJ, and ERV have no competing interests. AN has received a consulting fee from AVVA Pharmaceuticals, H Lundbeck A/S, Hoffman La Roche, honorarium for lecture Hoffman La Roche, Roche and hold a patent WO 2022/255915. Patent No. PCT/SE2022/050413 PET Tracers. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).